Please assess the completion status of the following clinical trial:

Trial Title: Real-World Evidence Registry to Assess Outcomes of Catheter Ablation for Atrial Fibrillation (DYNAMIC AF Registry)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with symptomatic, refractory or intolerant to at least one Class I or III AAD, paroxysmal atrial fibrillation (AF episode terminating spontaneously within 7 days) or symptomatic, refractory or intolerant to at least one Class I or III AAD, persistent AF (continuous AF sustained beyond 7-days and less than 1-year) who, in the opinion of the investigator, are candidates for ablation for AF. Refusal to take AADs for any reason is considered intolerant for the purposes of this protocol.~* Plans to undergo an RF catheter ablation procedure using an ablation catheter manufactured by Abbott~* De Novo ablation unless it is a repeat procedure for a subject whose index procedure is also included in the registry~* 18 years of age or older~* Able and willing to participate in baseline and follow up evaluations for the full length of the registry~Exclusion Criteria:~* Pregnant women~* Individual who cannot read or write, or those who cannot legally consent for themselves~* Participating in another clinical trial or has participated in a clinical trial within 30 days prior to screening that may interfere with this registry.~* Long-standing persistent AF (continuous AF sustained \>=1 year)~* Previous left atrial surgery for atrial fibrillation~* Having a repeat ablation, unless the subject's index ablation procedure is also included in the registry~* In the opinion of the investigator, any known contraindication to an ablation procedure or to any device or drug required for use during an ablation procedure as assessed by the investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Acute SOC Sites with Patients with paroxysmal or persistent atrial fibrillation (Type: None): Patients with symptomatic, refractory or intolerant to at least one Class I or III AAD, paroxysmal atrial fibrillation (AF episode terminating spontaneously within 7 days) or symptomatic, refractory or intolerant to at least one Class I or III AAD, persistent AF (continuous AF sustained beyond 7-days and less than 1-year) who, in the opinion of the investigator, are candidates for ablation for AF.
- Symptomatic Monitoring SOC Sites with Patients with paroxysmal or persistent atrial fibrillation (Type: None): Patients with symptomatic, refractory or intolerant to at least one Class I or III AAD, paroxysmal atrial fibrillation (AF episode terminating spontaneously within 7 days) or symptomatic, refractory or intolerant to at least one Class I or III AAD, persistent AF (continuous AF sustained beyond 7-days and less than 1-year) who, in the opinion of the investigator, are candidates for ablation for AF.
- Full Monitoring SOC Sites with Patients with paroxysmal or persistent atrial fibrillation (Type: None): Patients with symptomatic, refractory or intolerant to at least one Class I or III AAD, paroxysmal atrial fibrillation (AF episode terminating spontaneously within 7 days) or symptomatic, refractory or intolerant to at least one Class I or III AAD, persistent AF (continuous AF sustained beyond 7-days and less than 1-year) who, in the opinion of the investigator, are candidates for ablation for AF.

Based on this trial design, predict the completion outcome and termination type (if applicable).